GE HealthCare: first doses of Flyrcado delivered in the USA

(CercleFinance.com) - GE HealthCare announces that it has delivered the first doses of Flyrcado (flurpiridaz F 18), a novel positron emission tomography (PET MPI) myocardial perfusion imaging agent for the detection of coronary artery disease (CAD), to pioneering imaging centers in the United States.


This milestone follows recent FDA approval, with Flyrcado offering superior diagnostic efficacy to single-photon emission computed tomography (SPECT) MPI, the dominant method in nuclear cardiology.

Houston Methodist Hospital has launched a phased rollout, with full commercialization scheduled for the second quarter of 2025.

Flyrcado, whose extended half-life enables wider distribution, should reach all cardiac PET users by the end of 2025.

Copyright (c) 2025 CercleFinance.com. All rights reserved.